-
Estimating restricted mean treatment effects with stacked survival models
Authors:
Andrew Wey,
David Vock,
John Connett,
Kyle Rudser
Abstract:
The difference in restricted mean survival times between two groups is a clinically relevant summary measure. With observational data, there may be imbalances in confounding variables between the two groups. One approach to account for such imbalances is to estimate a covariate-adjusted restricted mean difference by modeling the covariate-adjusted survival distribution and then marginalizing over…
▽ More
The difference in restricted mean survival times between two groups is a clinically relevant summary measure. With observational data, there may be imbalances in confounding variables between the two groups. One approach to account for such imbalances is to estimate a covariate-adjusted restricted mean difference by modeling the covariate-adjusted survival distribution and then marginalizing over the covariate distribution. We demonstrate that the mean-squared error of the restricted mean difference is bounded by the mean-squared error of the covariate-adjusted survival distribution estimators. This implies that a better estimator of the covariate-adjusted survival distributions is associated with a better estimator of the restricted mean difference. Thus, this paper proposes estimating restricted mean differences with stacked survival models. Stacked survival models estimate a weighted average of several survival models by minimizing predicted error. By including a range of parametric and semi-parametric models, stacked survival models can effectively estimate a covariate-adjusted survival distribution and, therefore, the restricted mean treatment effect in a wide range of scenarios. We demonstrate through a simulation study that the new estimator can perform nearly as well as Cox regression when the proportional hazards assumption is satisfied and significantly better when proportional hazards is violated. The proposed estimator is also illustrated with data from the United Network for Organ Sharing to evaluate post-lung transplant survival between large and small-volume centers.
△ Less
Submitted 15 October, 2014;
originally announced October 2014.
-
The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM
Authors:
Joseph S. Koopmeiners,
Andrew Wey
Abstract:
The primary object of a phase I clinical trial is to determine the maximum tolerated dose (MTD). Typically, the MTD is identified using a dose-escalation study, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher dose levels until the MTD is identified. The continual reassessment method (CRM) is a popular model-based dose-escalati…
▽ More
The primary object of a phase I clinical trial is to determine the maximum tolerated dose (MTD). Typically, the MTD is identified using a dose-escalation study, where initial subjects are treated at the lowest dose level and subsequent subjects are treated at progressively higher dose levels until the MTD is identified. The continual reassessment method (CRM) is a popular model-based dose-escalation design, which utilizes a formal model for the relationship between dose and toxicity to guide dose-finding. Recently, it was shown that the CRM has a tendency to get "stuck" on a dose-level, with little escalation or de-escalation in the late stages of the trial, due to the long-memory property of the CRM. We propose the randomized CRM (rCRM), which introduces random escalation and de-escalation into the standard CRM dose-finding algorithm, as an approach to overcoming the long-memory property of the CRM. We discuss two approaches to random escalation and de-escalation and compare the operating characteristics of the rCRM to the standard CRM by simulation. Our simulation results show that the rCRM identifies the true MTD at a similar rate and results in a similar number of DLTs compared to the standard CRM, while reducing the trial-to-trial variability in the number of cohorts treated at the true MTD.
△ Less
Submitted 6 May, 2014;
originally announced May 2014.
-
Combining parametric, semi-parametric, and non-parametric survival models with stacked survival models
Authors:
Andrew Wey,
John Connett,
Kyle Rudser
Abstract:
For estimating conditional survival functions, non-parametric estimators can be preferred to parametric and semi-parametric estimators due to relaxed assumptions that enable robust estimation. Yet, even when misspecified, parametric and semi-parametric estimators can possess better operating characteristics in small sample sizes due to smaller variance than non-parametric estimators. Fundamentally…
▽ More
For estimating conditional survival functions, non-parametric estimators can be preferred to parametric and semi-parametric estimators due to relaxed assumptions that enable robust estimation. Yet, even when misspecified, parametric and semi-parametric estimators can possess better operating characteristics in small sample sizes due to smaller variance than non-parametric estimators. Fundamentally, this is a bias-variance tradeoff situation in that the sample size is not large enough to take advantage of the low bias of non-parametric estimation. Stacked survival models estimate an optimally weighted combination of models that can span parametric, semi-parametric, and non-parametric models by minimizing prediction error. An extensive simulation study demonstrates that stacked survival models consistently perform well across a wide range of scenarios by adaptively balancing the strengths and weaknesses of individual candidate survival models. In addition, stacked survival models perform as good as, or better than, the model selected through cross-validation. Lastly, stacked survival models are applied to a well-known German breast cancer study.
△ Less
Submitted 19 December, 2014; v1 submitted 30 September, 2013;
originally announced September 2013.
